Duloxetine
- Generic Name
- Duloxetine
- Brand Names
- Cymbalta, Drizalma, Irenka, Yentreve, Duloxetine Zentiva, Duloxetine Mylan, Duloxetine Lilly
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19NOS
- CAS Number
- 116539-59-4
- Unique Ingredient Identifier
- O5TNM5N07U
- Background
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor. It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
- Indication
Indicated for:
1) Management of Major Depressive Disorder.
2) Management of Generalized Anxiety Disorder.
3) Management of diabetic peripheral neuropathy.
4) Management of fibromyalgia.
5) Management of chronic musculoskeletal pain.
6) Management of osteoarthritis of the knee in adults.
7) Management of chronic lower back pain in adults.
8) Management of stress urinary incontinence in adult women.
Off-label uses include:
1) Management of chemotherapy-induced peripheral neuropathy.
2) Management of stress urinary incontinence in adult men after prostatectomy until recovery is complete.
- Associated Conditions
- Chronic Lower Back Pain (CLBP), Chronic Musculoskeletal Pain, Diabetic Peripheral Neuropathic Pain (DPN), Fibromyalgia, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Osteoarthritis of the Knee, Stress Urinary Incontinence (SUI)
- Associated Therapies
- -
Duloxetine Stress Urinary Incontinence Efficacy and Safety Study
- Conditions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 120
- Registration Number
- NCT00475397
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
Duloxetine vs Placebo in the Treatment of General Anxiety
- Conditions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2007-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 327
- Registration Number
- NCT00475969
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Indianapolis, Indiana, United States
Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction)
- First Posted Date
- 2007-05-09
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 18
- Registration Number
- NCT00471315
- Locations
- 🇺🇸
Digestive Disease Center, Medical University of South Carolina, Charleston, South Carolina, United States
Duloxetine for the Treatment of Obsessive Compulsive Disorder (OCD)
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT00464698
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Test the Use of Duloxetine for Pain in MS
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- Brown, Theodore R., M.D., MPH
- Target Recruit Count
- 38
- Registration Number
- NCT00457730
- Locations
- 🇺🇸
Evergreen Healthcare, Kirkland, Washington, United States
A Research Study Examining The Use Of Duloxetine In The Prevention Of Migraine Headache
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 27
- Registration Number
- NCT00443352
- Locations
- 🇺🇸
Jefferson Headache Center, Philadelphia, Pennsylvania, United States
The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT00438971
- Locations
- 🇺🇸
The Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston, Massachusetts, United States
Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 256
- Registration Number
- NCT00433290
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gothenburg, Sweden
Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain
- Conditions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT00425230
- Locations
- 🇺🇸
Micheal E. DeBakey Veterans Hospital, Houston, Texas, United States
Duloxetine Versus Placebo in Chronic Low Back Pain
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 236
- Registration Number
- NCT00424593
- Locations
- 🇳🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p, Rotterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.